Payment overview · 2025
General Payments
$1,640.38
69 reported records · 14 companies
Healthcare provider profile · identity verified
Vincent Dien Ho
Allopathic & Osteopathic Physicians|Family Medicine · ROSEMEAD, CA · NPI 1144249871
Verified facts
What the public records show
CMS Open Payments records show Vincent Dien Ho received $1,640.38 in general payments during 2025 across 69 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Paxlovid, Rybelsus, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 390 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 336 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 336 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $552.92 | 33.7% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $204.39 | 12.5% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $180.16 | 11.0% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $145.84 | 8.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $130.94 | 8.0% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $101.17 | 6.2% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $82.36 | 5.0% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $56.44 | 3.4% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $49.31 | 3.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.40 | 3.0% | 2 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $26.07 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.18 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.56 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.64 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,640.38 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $323.46 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $280.31 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $211.57 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $123.73 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $114.43 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $101.17 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.55 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $82.36 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $80.66 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $80.66 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $56.44 | 2 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $49.31 | 2 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $49.31 | 2 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $49.31 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.40 | 2 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 390 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 336 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 53 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
73 | 49 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
390 | 72 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
336 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
336 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2107 | 477 |
| Amlodipine Besylate | Amlodipine Besylate | 1228 | 274 |
| Losartan Potassium | Losartan Potassium | 1227 | 254 |
| Metformin Hcl | Metformin Hcl | 998 | 192 |
| Omeprazole | Omeprazole | 614 | 179 |
| Alendronate Sodium | Alendronate Sodium | 482 | 120 |
| Vascepa | Icosapent Ethyl | 481 | 83 |
| Atenolol | Atenolol | 469 | 94 |
| Nifedipine Er | Nifedipine | 463 | 94 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 462 | 199 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 453 | 92 |
| Meloxicam | Meloxicam | 422 | 135 |
| Amoxicillin | Amoxicillin | 417 | 259 |
| Azelastine Hcl | Azelastine Hcl | 397 | 132 |
| Farxiga | Dapagliflozin Propanediol | 390 | 72 |
| Celecoxib | Celecoxib | 365 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 354 | 71 |
| Montelukast Sodium | Montelukast Sodium | 350 | 82 |
| Jardiance | Empagliflozin | 336 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 322 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 309 | 80 |
| Baclofen | Baclofen | 305 | 126 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 303 | 70 |
| Januvia | Sitagliptin Phosphate | 278 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 49 |
| Icosapent Ethyl | Icosapent Ethyl | 262 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 240 | 43 |
| Simvastatin | Simvastatin | 225 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 210 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 206 | 74 |
| Famotidine | Famotidine | 190 | 53 |
| Ezetimibe | Ezetimibe | 186 | 32 |
| Gabapentin | Gabapentin | 168 | 46 |
| Glipizide | Glipizide | 159 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 60 |
| Lisinopril | Lisinopril | 152 | 35 |
| Donepezil Hcl | Donepezil Hcl | 145 | 32 |
| Allopurinol | Allopurinol | 125 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 27 |
| Folic Acid | Folic Acid | 107 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 107 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 106 | 31 |
| Fluocinonide | Fluocinonide | 105 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 18 |
| Azithromycin | Azithromycin | 99 | 78 |
| Meclizine Hcl | Meclizine Hcl | 99 | 63 |
| Metformin Hcl Er | Metformin Hcl | 97 | 17 |
| Finasteride | Finasteride | 88 | 24 |
| Carvedilol | Carvedilol | 87 | 17 |
| Kerendia | Finerenone | 84 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 70 |
| Naproxen | Naproxen | 77 | 49 |
| Clonidine Hcl | Clonidine Hcl | 74 | 36 |
| Prolia | Denosumab | 73 | 49 |
| Raloxifene Hcl | Raloxifene Hcl | 71 | 12 |
| Eliquis | Apixaban | 69 | 12 |
| Furosemide | Furosemide | 68 | 29 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 66 | 13 |
| Colchicine | Colchicine | 65 | 25 |
| Glimepiride | Glimepiride | 65 | 11 |
| Sertraline Hcl | Sertraline Hcl | 64 | 17 |
| Benazepril Hcl | Benazepril Hcl | 63 | 16 |
| Lorazepam | Lorazepam | 63 | 16 |
| Ibuprofen | Ibuprofen | 59 | 48 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | suppressed |
| Tradjenta | Linagliptin | 58 | suppressed |
| Hydrocortisone | Hydrocortisone | 57 | 29 |
| Acarbose | Acarbose | 56 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 56 | 31 |
| Temazepam | Temazepam | 56 | 11 |
| Vemlidy | Tenofovir Alafenamide | 54 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Rybelsus | Semaglutide | 53 | 11 |
| Cyclosporine | Cyclosporine | 52 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 50 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 20 |
| Lansoprazole | Lansoprazole | 48 | suppressed |
| Prednisone | Prednisone | 48 | 41 |
| Telmisartan | Telmisartan | 47 | suppressed |
| Febuxostat | Febuxostat | 46 | 11 |
| Trazodone Hcl | Trazodone Hcl | 46 | 13 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 45 | 37 |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 43 | 14 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 43 | suppressed |
| Creon | Lipase/Protease/Amylase | 42 | 12 |
| Loperamide | Loperamide Hcl | 42 | 37 |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Ranolazine Er | Ranolazine | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 36 |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 34 | 12 |
| Tramadol Hcl | Tramadol Hcl | 34 | 23 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | 16 |
| Cephalexin | Cephalexin | 33 | 28 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | 17 |
| Methimazole | Methimazole | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 31 | 16 |
| Nitroglycerin | Nitroglycerin | 31 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 15 |
| Indomethacin | Indomethacin | 30 | 13 |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | 11 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 11 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Triazolam | Triazolam | 19 | suppressed |
| Ciclopirox | Ciclopirox | 18 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | 11 |
| Restasis | Cyclosporine | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Proctozone-Hc | Hydrocortisone | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Cilostazol | Cilostazol | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Latanoprost | Latanoprost | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Silodosin | Silodosin | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,640.38 · 69 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Cequa, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Grastek, JARDIANCE, Kerendia, Korlym, MOUNJARO, OTEZLA, Odactra, Ozempic, PAXLOVID, REPATHA, Ragwitek, Rybelsus, ZENPEP, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error